Differential knockdown of TGF-β ligands in a three-dimensional co-culture tumor- stromal interaction model of lung cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Horie, Masafumi ^a   Saito, Akira ^a,b   Noguchi, Satoshi ^a   Yamaguchi, Yoko ^c   Ohshima, Mitsuhiro ^d   Morishita, Yasuyuki ^a   Suzuki, Hiroshi I ^a   Kohyama, Tadashi ^a,e   Nagase, Takahide ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NIHON UNIVERSITY   (Japan)

^d OHU UNIVERSITY   (Japan)

^e TEIKYO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Gel contraction assay; Lentivirus vector; MicroRNA; RNA interference; TGF ; Three dimensional co culture

Indexed keywords

LENTIVIRUS VECTOR; MICRORNA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL INTERACTION; CELL INVASION; CELL TYPE; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG CANCER; LUNG FIBROBLAST; MITOSIS INHIBITION; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STROMA CELL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE SILENCING; GENETICS; LENTIVIRINAE; LUNG TUMOR; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLASTS; GENE KNOCKDOWN TECHNIQUES; HUMANS; LENTIVIRUS; LUNG NEOPLASMS; MICRORNAS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

EID: 84905863057     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-580     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
3. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, Ishikawa Y, Kimura H, Mitsudomi T, Tanio Y, Mano H. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363(18):1734-1739.
4. Micke P, Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?. Lung Cancer 2004, 45(Suppl 2):S163-S175.
5. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004, 4(10):806-813.
6. Massague´ J. TGFbeta in Cancer. Cell 2008, 134(2):215-230.
7. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006, 6(7):506-520.
8. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010, 10(6):415-424.
9. Saito A, Suzuki HI, Horie M, Ohshima M, Morishita Y, Abiko Y, Nagase T. An integrated expression profiling reveals target genes of TGF-beta and TNF-alpha possibly mediated by microRNAs in lung cancer cells. PLoS One 2013, 8(2):e56587.
10. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119(6):1420-1428.
11. Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999, 86(9):1712-1719.
12. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001, 91(5):964-971.
13. Davidson BL, McCray PB. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011, 12(5):329-340.
14. Cullen BR. Transcription and processing of human microRNA precursors. Mol Cell 2004, 16(6):861-865.
15. Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 2002, 9(6):1327-1333.
16. Hamasaki T, Suzuki H, Shirohzu H, Matsumoto T, D'Alessandro-Gabazza CN, Gil-Bernabe P, Boveda-Ruiz D, Naito M, Kobayashi T, Toda M, Mizutani T, Taguchi O, Morser J, Eguchi Y, Kuroda M, Ochiya T, Hayashi H, Gabazza EC, Ohgi T. Efficacy of a novel class of RNA interference therapeutic agents. PLoS One 2012, 7(8):e42655.
17. Horie M, Saito A, Mikami Y, Ohshima M, Morishita Y, Nakajima J, Kohyama T, Nagase T. Characterization of human lung cancer-associated fibroblasts in three-dimensional in vitro co-culture model. Biochem Biophys Res Commun 2012, 423(1):158-163.
18. Wen FQ, Kohyama T, Skold CM, Zhu YK, Liu X, Romberger DJ, Stoner J, Rennard SI. Glucocorticoids modulate TGF-beta production by human fetal lung fibroblasts. Inflammation 2003, 27(1):9-19.
19. Jakowlew SB, Mathias A, Chung P, Moody TW. Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ 1995, 6(4):465-476.
20. Saito RA, Watabe T, Horiguchi K, Kohyama T, Saitoh M, Nagase T, Miyazono K. Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells. Cancer Res 2009, 69(7):2783-2791.
21. Navab R, Strumpf D, Bandarchi B, Zhu CQ, Pintilie M, Ramnarine VR, Ibrahimov E, Radulovich N, Leung L, Barczyk M, Panchal D, To C, Yun JJ, Der S, Shepherd FA, Jurisica I, Tsao MS. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A 2011, 108(17):7160-7165.
22. Campbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky DV, Brandsma CA, Suzuki M, Gosselink JV, Liu G, Alekseyev YO, Xiao J, Zhang X, Hayashi S, Cooper JD, Timens W, Postma DS, Knight DA, Marc LE, James HC, Avrum S. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med 2012, 4(8):67.
23. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, Pennathur S, Martinez FJ, Thannickal VJ. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009, 15(9):1077-1081.
24. Bragg AD, Moses HL, Serra R. Signaling to the epithelium is not sufficient to mediate all of the effects of transforming growth factor beta and bone morphogenetic protein 4 on murine embryonic lung development. Mech Dev 2001, 109(1):13-26.
25. Saito RA, Micke P, Paulsson J, Augsten M, Peña C, Jo¨nsson P, Botling J, Edlund K, Johansson L, Carlsson P, Jirstro¨m K, Miyazono K, Ostman A. Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Res 2010, 70(7):2644-2654.
26. Kage H, Sugimoto K, Sano A, Kitagawa H, Nagase T, Ohishi N, Takai D. Suppression of transforming growth factor beta1 in lung alveolar epithelium-derived cells using adeno-associated virus type 2/5 vectors to carry short hairpin RNA. Exp Lung Res 2011, 37(3):175-185.
27. Hawinkels LJ, Ten Dijke P. Exploring anti-TGF-beta therapies in cancer and fibrosis. Growth Factors 2011, 29(4):140-152.
28. Scagliotti GV, Ilaria R, Novello S, von Pawel J, Fischer JR, Ermisch S, de Alwis DP, Andrews J, Reck M, Crino L, Eschbach C, Manegold C. Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study. J Thorac Oncol 2012, 7(6):1053-1057.
29. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 2007, 117(5):1305-1313.
30. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V, Poverennova I, Zaaroor M, Jachimczak P, Ludwig S, Schmaus S, Heinrichs H, Schlingensiepen KH. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-Oncology 2011, 13(1):132-142.
31. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006, 24(29):4721-4730.